2011全球体外诊断（IVD）市场研究报告英文版

jackli_ib

2011全球体外诊断（IVD）市场研究报告英文版
I. M&A deal values rise
sharply as IVD market
leaders reshuffle 3
3 Key findings
4 Deal value rises
4 Deal volume remains flat
5 Five factors drive top-10 deals
9 Top-player ranks expected to reshuffle
11 IVD an acquisition target for pharma?
14 Outlook
II. Companion partnerships
with pharma increase 17
17 Key findings
18 Diagnostics partnerships with pharma increase
sharply during 2009–2010
18 Regulators, payers, and pharma drive rising
demand for companion diagnostics
19 Challenges to the economics of diagnostics
remain, despite strong demand
24 Pharma partners
25 Diagnostics partners:
Medium-sized or niche IVD players lead deals
with pharma, but a few larger companies
seal partnerships
27 Disease areas
29 Outlook
III. Early detection provides
new prospects for
improved outcomes 33
33 Key findings
34 Tests for early detection have not created
many headlines in recent years. Could this
change soon?
35 In principle, the case for early detection should
be straightforward
35 In practice, issues with screening standards
have created scepticism
36 The emergence of a wave of new IVD tests creates
an opportunity to revisit early detection
39 The performance of new IVD tests needs to be
confirmed
40 IVD tests for early detection could generate
blockbuster revenues
40 Health economics will be a key driver to
achieve reimbursement and market adoption
40 A narrow positioning of the test may accelerate
market access
42 IVD majors have not been involved in origination
but have a key role to play in commercialisation
43 Is early detection an opportunity for pharma?
44 Outlook
IV. Ten recent events
impacting personalised
medicine 47
47 Key findings
48 Event review
V. Case studies 55
55 Case study 1—MDxHealth
58 Case study 2—Genclis
Conclusion 61
Acknowledgements 62
Diagnostics 2011 PwC

coolish

支持!!!很好很有用的资料